bullish

Sumitomo Pharma (4506 JP): Q1FY25 Result Shows Early Sign of Performance Reversal

529 Views01 Aug 2024 23:16
Sumitomo Pharma reported double-digit revenue growth in Q1FY25, driven by North America. Operating loss narrowed. Net profit stood at ¥16B in Q1FY25. The company is expected to revise FY25 guidance.
What is covered in the Full Insight:
  • Introduction
  • Q1FY25 Financial Performance
  • Key Products Overview
  • Cost Management and Structural Reforms
  • Future Outlook and Catalysts
Boomeranged on Thu, 3 Oct 2024 16:45
Sumitomo Pharma shares gained 37% in just two months. Book partial profit and hold core position. Valuation is still cheap and outlook is still positive. H1FY25 result announcement is on October 30.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
x